Pulse Biosciences Crescita futura

Criteri Future verificati 2/6

Si prevede che Pulse Biosciences aumenterà gli utili e i ricavi rispettivamente del 19.5% e 57.3% all'anno, mentre si prevede che l'EPS crescerà del 20.6% all'anno.

Informazioni chiave

19.5%

Tasso di crescita degli utili

20.58%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	16.1%
Tasso di crescita dei ricavi	57.3%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	05 Mar 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform

Feb 09Catalysts About Pulse Biosciences Pulse Biosciences develops and commercializes medical devices that use proprietary nanosecond pulse field ablation technology for soft tissue and cardiac applications. What are the underlying business or industry changes driving this perspective?

Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans

Dec 21

Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation

Jun 12

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:PLSE - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2028	41	-81	-77	N/A	1
12/31/2027	13	-100	-75	N/A	2
12/31/2026	3	-92	-68	N/A	2
12/31/2025	0	-73	-54	-54	N/A
9/30/2025	0	-75	-49	-49	N/A
6/30/2025	N/A	-68	-45	-44	N/A
3/31/2025	N/A	-60	-40	-40	N/A
12/31/2024	N/A	-54	-36	-36	N/A
9/30/2024	N/A	-46	-34	-34	N/A
6/30/2024	N/A	-44	-36	-35	N/A
3/31/2024	N/A	-43	-36	-36	N/A
12/31/2023	N/A	-42	-33	-33	N/A
9/30/2023	0	-39	-34	-34	N/A
6/30/2023	0	-47	-35	-34	N/A
3/31/2023	0	-51	-38	-38	N/A
12/31/2022	1	-59	-47	-47	N/A
9/30/2022	2	-65	-52	-52	N/A
6/30/2022	2	-61	-55	-54	N/A
3/31/2022	2	-62	-59	-58	N/A
12/31/2021	1	-64	-55	-54	N/A
9/30/2021	1	-62	-51	-51	N/A
6/30/2021	N/A	-61	-46	-46	N/A
3/31/2021	N/A	-57	-38	-37	N/A
12/31/2020	N/A	-50	-36	-35	N/A
9/30/2020	N/A	-50	-35	-35	N/A
6/30/2020	N/A	-49	-35	-35	N/A
3/31/2020	N/A	-49	-37	-36	N/A
12/31/2019	N/A	-47	-35	-34	N/A
9/30/2019	N/A	-42	N/A	-31	N/A
6/30/2019	N/A	-41	N/A	-30	N/A
3/31/2019	N/A	-39	N/A	-26	N/A
12/31/2018	N/A	-38	N/A	-24	N/A
9/30/2018	N/A	-37	N/A	-22	N/A
6/30/2018	N/A	-34	N/A	-18	N/A
3/31/2018	N/A	-31	N/A	-14	N/A
12/31/2017	N/A	-26	N/A	-11	N/A
9/30/2017	N/A	-20	N/A	-9	N/A
6/30/2017	N/A	-15	N/A	-8	N/A
3/31/2017	N/A	-11	N/A	-9	N/A
12/31/2016	N/A	-10	N/A	-8	N/A
9/30/2016	N/A	-8	N/A	-7	N/A
6/30/2016	N/A	-6	N/A	-6	N/A
3/31/2016	N/A	-4	N/A	-4	N/A
12/31/2015	N/A	-3	N/A	-3	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che PLSE rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che PLSE rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che PLSE rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di PLSE ( 57.3% all'anno) crescerà più rapidamente del mercato US ( 10.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di PLSE ( 57.3% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di PLSE è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/03/10 11:44
Prezzo dell'azione a fine giornata	2026/03/10 00:00
Utili	2025/12/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github, abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Pulse Biosciences, Inc. è coperta da 4 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Anthony Vendetti	Maxim Group
Anthony Petrone	Mizuho Securities USA LLC
Suraj Kalia	Oppenheimer & Co. Inc.

Pulse Biosciences Crescita futura

Criteri Future verificati 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

No longer forecast to breakeven

No longer forecast to breakeven

Consensus revenue estimates fall by 31%

Consensus forecasts updated

Price target decreased to US$11.17

Consensus forecasts updated

Recent updates

Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study Of Benign Thyroid Nodule Ablation

No longer forecast to breakeven

Pulse Biosciences, Inc. has withdrawn its Follow-on Equity Offering in the amount of $60 million.

Chief Commercial Officer notifies of intention to sell stock

Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform

New major risk - Share price stability

Pulse Biosciences, Inc. Presents Late-Breaking Data from nPulse™? Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Pulse Biosciences, Inc. to Report Q4, 2025 Results on Feb 19, 2026

No longer forecast to breakeven

Pulse Biosciences, Inc. Appoints Maria Sainz to Its Board of Directors, Effective January 9, 2026

Pulse Biosciences Selects to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans

Pulse Biosciences, Inc. Announces FDA Ide Approval to Initiate Its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc., Annual General Meeting, Dec 09, 2025

Pulse Biosciences, Inc. Announces First Enrollment in the NANOCLAMP AF Study

Pulse Biosciences, Inc. to Report Q3, 2025 Results on Nov 05, 2025

Pulse Biosciences, Inc. Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

CTO & Director exercised options and sold US$822k worth of stock

Independent Co-Chairman recently bought US$2.6m worth of stock

Pulse Biosciences Announces Fda Ide Approval to Initiate Its Nspfa Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc. Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Pulse Biosciences, Inc. Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Pulse Biosciences, Inc. to Report Q2, 2025 Results on Aug 12, 2025

New major risk - Revenue and earnings growth

CTO & Director recently sold US$486k worth of stock

Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation

Pulse Biosciences, Inc. to Report Q1, 2025 Results on May 08, 2025

Pulse Biosciences, Inc. to Report Q4, 2024 Results on Mar 27, 2025

Independent Director exercised options to buy US$1.3m worth of stock.

We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Pulse Biosciences, Inc. Announces the Appointment of Jon Skinner as Chief Financial Officer

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Pulse Biosciences, Inc. Appoints Paul A. LaViolette as Chief Executive Officer

Executive Co-Chairman exercised options to buy US$94m worth of stock.

Executive Co-Chairman recently bought US$972k worth of stock

Pulse Biosciences, Inc. Announces Positive Clinical Data Presented At the American Thyroid Association

Pulse Biosciences, Inc. Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Pulse Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Pulse Biosciences, Inc. announced delayed 10-Q filing

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought US$86k worth of stock

Pulse Biosciences Stock: Signs Of Life Following Q1 Update

Pulse Biosciences, Inc Announces CEO Changes

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought US$105k worth of stock

Executive Chairman exercised options to buy US$68k worth of stock.

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023